ESMO 2018

Area: Oncology

Location: Munich, Germany

Date: October 19 to October 23

Description:

Annual Congress of the European Society for Medical Oncology.


Search in Scientific Content:
Date
Filters:
Biomarkers
9:23

Biomarkers in immuno-oncology

Presenter: Manfred Dietel
Oncology
First-Line
3:53

First-Line Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Interim Results From the Phase 3 KEYNOTE-048 Study

Presenter: Barbara Burtness
Oncology
Updates on
4:58

Updates on NETs and endocrine tumours

Presenter: Enrique Grande
Oncology
Clinical i
7:54

Clinical implementation of PI3K inhibitors

Presenter: Evandro de Azambuja
Oncology
Targeted t
6:17

Targeted therapy and EGFR mutations

Presenter: Benjamin Besse
Oncology
Highlitghs
8:30

Highlitghs of ESMO - IO and targeted therapy in lung cancer

Presenter: Solange Peters
Oncology
Two illust
10:33

Two illustrative and interactive tumour board style case study discussions

Presenter: Christine Brezden-Masley
Oncology
Update on
2:29

Update on the latest clinical practice referring to NETs

Presenter: Angela Lamarca
Oncology
New result
4:36

New results in Head and Neck Cancer

Presenter: Jean-Pascal Machiels
Oncology
Biomarkes
5:59

Biomarkes in Immuno-Oncology (PDL-1 testing)

Presenter: Federico Cappuzzo
Oncology

How to manage pretreated mCRC patients: An expert’s approach

Presenter: Julien Taieb
Oncology
IMpassion1
2:46

IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC) IMPassion130

Presenter: Peter Schmid
Oncology
Overall su...
3:56

Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3

Presenter: Massimo Cristofanilli
Oncology
Alpelisib
3:20

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase III SOLAR-1 trial

Presenter: Fabrice André
Oncology
IMpassion1
1:24

IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC) IMPassion130

Presenter: Giuseppe Curigliano
Oncology
Use of imm...
7:40

Use of immune checkpoint inhibitors in early stage NSCLC – Next generation trials in NSCLC

Presenter: Giorgio Scagliotti
Oncology

SABCS 2020

2020-12-08 - 2020-12-11
Online, Virtual

ESMO 2020

2020-09-19 - 2020-09-21
Online, Virtual

ASCO 2020

2020-05-29 - 2020-05-31
Online, Virtual

ESMO 2019

2019-09-27 - 2019-10-01
Barcelona, Spain

ASCO 2019

2019-05-31 - 2019-06-04
Chicago, United States

EADO 2019

2019-04-24 - 2019-04-27
Paris, France

BCC 2019

2019-03-20 - 2018-03-23
Vienna, Austria

SABCS 2018

2018-12-04 - 2018-12-08
San Antonio, United States

ASCO 2018

2018-06-01 - 2018-06-05
Chicago, United States